 |
|
|
|
 |
|
|
| Article 1 to 10 out of 43 concerning Frost & Sullivan
|
-
Western European in vitro diagnostics market sustained by new technologies
(07/02/2008)
Market earns $12.65 billion in 2014
Despite issues such as rising R&D costs, poor reimbursement and a decline in prices, the emergence of new technologies is boosting the Western European in vitro diagnostics (IVD) markets. While the introduction of automation and integrated platforms ...
-
Development of effective, novel treatments critical to ensure growth in the european bladder cancer therapeutics market
(10/05/2007)
None of the developments in the bladder cancer area have improved the long-term survival rate of patients, with research results also remaining disappointing. Patients still die from muscle invasive disease, despite aggressive therapy with curative ...
-
Blockbusters Going off Patent - Opportunities for Generics
(07/17/2007)
Growing Demand for Inexpensive, Effective Drugs and Continuing Patent Expiries ProvideGrowth Prospects for the European Generics Market
With an ageing population and expensive drugs driving healthcare costs upwards, generic medicines are gaining significance in Europe. The governments are under tremendous pressure to reduce healthcare expenditure. In this scenario, generics are ...
-
GATC refuses Frost & Sullivan Marketing Strategy Leadership Award
(10/02/2006)
GATC Biotech AG refuses the "2006 Frost & Sullivan Marketing Strategy Leadership Award". The award was presented by Frost & Sullivan in recognition of GATC's marketing strategies in the European bioinformatics market.In order for GATC to publicise ...
-
Novel Products to Inject Momentum into European Vaccines Market
(04/06/2006)
The European vaccines market is currently in a growth phase. While it faces significant challenges in terms of low profit margins, complex manufacturing and fragmented competition, the market is still forecast to average a healthy compound annual ...
-
Focus on Creating a Knowledge Based Economy Ensures Increased Funding for Life Sciences
(10/12/2005)
European Commissions Framework 6 Programme (FP6) Sets Thematic Priority for Life Sciences
Given the rapid advances in biological sciences, the European Commission (EC) under its framework 6 programme (FP6) has set a strategic thematic priority for life sciences along with biotechnology and health. While this is expected to significantly ...
-
Participants in the Gene Therapy Market Discover New Ways to Improve Clinical Efficiency and Generate Revenue
(08/01/2005)
The gene therapy market has had limited success with products during the clinical development process. Due to toxicological complications and poor therapy efficacy, healthcare authorities have suspended several gene therapy trials worldwide. ...
-
Pharmaceutical Industry Faces Multiple Challenges
(05/30/2005)
Future lies in Drug Pipeline Sustainability
High clinical development costs coupled with declining drug discovery success rates are causing productivity levels to fall in the global pharmaceuticals industry. The imminent patent expiry of several major blockbuster drugs and the related rise of ...
-
Cellectricon AB to Receive the 2004 Frost & Sullivan Market Penetration Leadership Award
(02/09/2005)
Cellectricon AB is the recipient of the 2004 Frost & Sullivan Market Penetration Leadership Award in recognition of its comprehensive and distinctive portfolio of cell-based assay products. Outstanding product offerings have placed the company in a ...
-
Outstanding Product Differentiation and Innovation Underpin Frost & Sullivan Award to Pharma/Biotech Supplier Sartorius AG
(12/14/2004)
For its dedication in producing a full spectrum of downstream processing products and services through technical innovation and industrial collaboration, Frost & Sullivan confers the 2004 Product Differentiation Innovation Award in the arena of ...
Additional information
Frost & Sullivan
Frankfurt, Germany
Company
|
|
|
|
|
|
Top
